KDA Group and ID Solution Sign a Letter Of Intent for Distribution of Screening Technology Products

Tickers: XTSX:KDA
Tags: #Mining

Thetford Mines, Quebec - TheNewswire - July 15, 2020 - KDA Group Inc. (TSXV:KDA) ("KDA" or the "Corporation") is pleased to announce that the Corporation has signed an exclusive letter of intent (the "Letter of Intent") with ID Solution Inc. ("ID Solution") for the sale and distribution of screening technology products (the "Products") in the field of medical safety and security for pharmacies, laboratories, nursing homes, hospitals, clinics and any other building for the Canadian market in the healthcare sector. These Products are of particular interest during these times of pandemic associated to COVID-19.

These Products will enable medical and other businesses to make facilities and buildings safer through biometrics with thermal detection, intelligent hand washing and staff entry/exit management. These Products will also reduce contact between people, reduce surveillance personnel, better manage employee work time and, above all, increase employee safety in their work environment.

The Letter of Intent targets, among others, innovative Products in the field of medical safety and security for which ID Solution designs and manufactures said Products for international sales and distribution including the Canadian and American markets. These Products are of varied nature and have the objective to help, assist and contribute to the detection, protection and/or control of COVID-19. KDA will use its pharmaceutical and medical expertise held through its various divisions to distribute these Products.

"We are very proud once again to fulfill our mission to the pharmaceutical and healthcare community through this Letter of Intent to procure and supply medical safety and security Products related to COVID-19. By partnering with ID Solution, we are proud to be associated to a company with which we will be able to pool our expertise, knowledge and efforts in this everyday struggle to detect, prevent and reduce the spread of the COVID-19 pandemic," said Marc Lemieux, Chief Executive Officer of KDA.

ABOUT KDA GROUP

KDA Group is a leading innovation and specialized solution provider in the pharmaceutical market. Today, it is a respected name for quality and expertise among the different stakeholders in the pharmaceutical and medical sector. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.

- 30 -

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

INFORMATION

Marc Lemieux

Chief Executive Officer

514 622-7370

info@groupekda.ca

Copyright (c) 2020 TheNewswire - All rights reserved.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.